Abbreviations & Acronyms CIS = carcinoma in situ CSS = cancer-specific survival IQR = interquartile range MTT = methylthiazolyldiphenyltetrazolium bromide PFS = progression-free survival RFS = recurrence-free survival RPT = renal pelvic tumor siRNA = small interfering ribonucleic acid TMA = tissue microarray UCB = urothelial carcinoma of the bladder UDP = uridine 5d iphosphate UGT = uridine 5´diphospho-glucuronosyltransferase UT = ureteral tumor UUTUC = upper urinary tract urothelial carcinoma ) of tumors, which was significantly (P < 0.001) lower than in benign urothelial tissues (98.8%; 3.5% 1+, 18.8% 2+, 76.4% 3+). All 37 (100%) non-muscle-invasive versus 55 (88.7%) of 62 muscle-invasive tumors (P = 0.043) were immunoreactive for uridine 5´diphospho-glucuronosyltransferase 1A. The rates of moderate-to-strong uridine 5´diphospho-glucuronosyltransferase 1A expression and its positivity were also strongly associated with the absence of concomitant carcinoma in situ (P = 0.034) and lymphovascular invasion (P = 0.016), respectively. However, there were no statistically significant associations between uridine 5´diphospho-glucuronosyltransferase 1A expression and tumor grade or pN/M status. Uridine 5d iphospho-glucuronosyltransferase 1A loss in M0 tumors was strongly associated with lower progression-free survival (P < 0.001) and cancer-specific survival (P < 0.001) rates. Multivariate analysis further identified a strong correlation of uridine 5´diphospho-glucuronosyltransferase 1A positivity with reduced cancer-specific mortality (hazard ratio 0.28, P = 0.018). Meanwhile, uridine 5´diphospho-glucuronosyltransferase 1A knockdown in urothelial cancer cells resulted in significant increases in their viability and migration. Conclusions: These results suggest a preventive role of uridine 5´diphospho-glucuronosyltransferase 1A signals in the development and progression of upper urinary tract urothelial carcinoma. Loss of uridine 5´diphospho-glucuronosyltransferase 1A expression might serve as an independent predictor of poor prognosis in patients with upper urinary tract urothelial carcinoma.
Introduction
UUTUC is a relatively rare disease accounting for just 5-10% of all urothelial carcinomas, whereas UCB is a common malignancy, especially in men. 1 Because of its preponderance, clinical evidence for UCB has been applied to decision-making on UUTUC. Indeed, only a few major urological or oncological associations (e.g. Japanese Urological Association, European Association of Urology) have published a guideline for UUTUC separate from that for UCB. 1, 2 Although nephroureterectomy has been a standard treatment for UUTUC, lymphadenectomy as well as neoadjuvant or adjuvant chemotherapy is also considered, especially in patients with high-risk disease. Conversely, selected patients with low-risk UUTUC might benefit from a more conservative approach, such as endoscopic ablation or segmental resection. For this purpose, several prognostic markers for UUTUC have been investigated. However, none of these have been used in clinical practice. 3 UGTs belong to a superfamily of major phase II drug metabolism enzymes that catalyze the glucuronidation of numerous endobiotics and xenobiotics. Human UGTs are divided into UGT1A, UGT2A and UGT2B based on gene sequence homology. Of these subtypes, UGT1A is known to play a more significant role in preventing bladder tumorigenesis by involving metabolism of, for instance, aromatic amines, the major carcinogen of the lower urinary tract, and detoxifying these carcinogenic compounds. 4 We and others have shown that UGT1A expression is downregulated in UCBs compared with corresponding normal urothelial tissues in both mRNA 5 and protein [6] [7] [8] levels. In a chemically induced bladder cancer model in mice, knockout of a transcription factor, Nrf2, resulted in reduced UGT1A expression and increased tumor incidence. 9 These results support the preventive role of UGT1A in the development of UCB.
A recent genome-wide association study showed UGT1A as new susceptible loci for UCB, 10 and subsequent studies confirmed the observation in different cohorts. [11] [12] [13] In addition, a variant of UGT1A1 with low-activity promoter was associated with a higher risk of tumor recurrence in patients with non-muscle-invasive UCB.
14 Similarly, using immunohistochemistry, we showed that UGT1A expression could predict tumor recurrence in patients with non-muscle-invasive UCB, as well as cancer-specific mortality in those with muscle-invasive disease. 8 Thus, UGT1A was shown to be an important prognosticator for UCB. However, the prognostic significance of UGT1A in UUTUC remains uncertain. The aim of the present study was to examine the association between UGT1A expression and clinicopathological features of UUTUC.
Methods
Patients and tissue samples UUTUC TMA was constructed with spotted triplicate samples representing dominant tumors and paired normal-appearing urothelial tissues from 99 patients who underwent radical nephroureterectomy carried out at Osaka General Medical Center, Osaka, Japan, as described previously. 15 Appropriate approval was obtained from the institutional review board before construction and use of the TMA. Clinicopathological data of these 99 patients described previously are shown in Table 1 . 15, 16 None of the patients had received therapy with radiation or anticancer drugs before the collection of the tissues included in the TMA.
Immunohistochemistry
Immunohistochemical staining was carried out on the sections (5-lm thick) from the UUTUC TMA, using a primary antibody to UGT1A (H300 clone; diluted 1:100; Santa Cruz Biotechnology, Dallas, TX, USA), as we described previously. 7, 8, 17 An optimal condition for the stain was determined in control tissues. All the stains were manually scored by one pathologist (HM) blinded to patient identity. The German Immunoreactive Score (0-12) was calculated by multiplying the percentage of immunoreactive cells (0% = 0; 1-10% = 1; 11-50% = 2; 51-80% = 3; 81-100% = 4) by staining intensity (negative = 0; weak = 1; moderate = 2; strong = 3). Cores with the immunoreactive score of 0-1, 2-4, 6-8 and 9-12 were considered negative (0), weakly positive (1+), moderately positive (2+) and strongly positive (3+), respectively.
Cell line and transfection of siRNA
A human bladder urothelial cancer cell line, UMUC3, was originally obtained from the American Type Culture Collection and was recently authenticated by the institutional core facility. UMUC3 cells were maintained in Dulbecco's modified Eagle's medium (Mediatech, Manassas, VA, USA) supplemented with 10% fetal bovine serum at 37°C in a humidified atmosphere of 5% CO 2 . These cells were transfected with control-siRNA or UGT1A-siRNA (sc-44538; Santa Cruz Biotechnology), using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA), and were used for further assays.
Cell viability and scratch wound-healing assays
We used the MTT assay to assess cell viability. Cells (2 9 10 3 ) seeded in 96-well plates and transfected with a siRNA were cultured for 48 h, and then incubated with 0.5 mg/mL of MTT (Sigma-Aldrich, St. Louis, MO, USA) in 100 lL of medium for 3 h at 37°C. MTT was dissolved by dimethyl sulfoxide, and the absorbance was measured at a wavelength of 570 nm with background subtraction at 630 nm.
We then used scratch wound-healing assay to assess cell migration. Cells transfected with a siRNA at a density of 90-100% confluence in 12-well plates were scratched manually with a sterile 200-lL plastic pipette tip, cultured for 24 h, fixed with methanol and stained with 0.1% crystal violet. The width of the wound area was quantitated, using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Statistical analysis
Fisher's exact test was used to evaluate the association between categorized variables. The Mann-Whitney U-test was used to assess differences in variables with ordered distribution. The rates of RFS, PFS and CSS were calculated by the Kaplan-Meier method, and comparisons were made by the log-rank test. The Cox proportional hazards model was used to determine statistical significance of predictors in a multivariate setting. P-values <0.05 were considered to be statistically significant.
Results

Immunoreactivity in benign and tumor tissues
We immunohistochemically investigated the expression of UGT1A in 99 UUTUC specimens, as well as 85 corresponding normal-appearing urothelial tissues. Positive signals were detected predominantly in the cytoplasm of non-neoplastic and neoplastic epithelial cells ( Fig. 1 ), but stromal cells and immune cells were mostly negative for UGT1A.
The expression status in benign versus tumor tissues is summarized in Figure 2 ). Overall, the levels of UGT1A expression were significantly lower in tumors than in benign tissues (P < 0.001).
Immunoreactivity and clinicopathological features
The levels of UGT1A expression in UUTUCs according to clinicopathological features are shown in Table 1 . Pathological T stage was inversely correlated with UGT1A expression (P = 0.002). Specifically, all 37 (100%) non-muscle-invasive versus 55 (88.7%) of 62 muscle-invasive tumors (P = 0.043) were positive for UGT1A. Lymphovascular invasion was also more often (P = 0.016) seen in UGT1A-negative tumors ( ) of 101 non-neoplastic urothelial tissues in the bladder, which was not significantly different from its expression levels in the non-neoplastic urothelium in the renal pelvis, ureter or both. 8 In addition, there were no significant associations between UGT1A levels in non-neoplastic urothelial tissues and clinicopathological features, including pT stage, lymphovascular invasion, concomitant CIS and hydronephrosis (data not shown).
Immunoreactivity and prognostic significance
Next, we investigated possible associations between UGT1A expression and patient outcomes. To more accurately assess the role of UGT1A expression in tumor recurrence or progression, those with M1 (n = 4) or MX (n = 5) disease were excluded from the analyses. Kaplan-Meier and log-rank tests showed no significant associations between UGT1A levels and tumor recurrence in the bladder (Fig. 3a) . By contrast, reduced UGT1A expression strongly correlated with lower PFS (0 vs 1+/2+/3+, P < 0.001; 0/1+ vs 2+/3+, P = 0.014; Fig. 3b ) and CSS (0 vs 1+/2+/3+, P < 0.001; 0/1+ vs 2+/3+, P = 0.029; Fig. 3c) rates. As the majority of cause-specific deaths were seen in patients with pT3-4 tumor, we determined the prognostic value of UGT1A expression in this subpopulation (i.e. pT3-4pN0-2M0). As shown in Figure 3d , UGT1A negativity was strongly associated with a lower CSS rate (P < 0.001). Although UGT1A expression levels were significantly elevated in RPT than in UT, CSS rates were not statistically different between our cohorts of patients with RPT versus UT (Fig. 4a ). When patients with RPT (0 vs 1+/ 2+/3+, P < 0.001; 0/1+ vs 2+/3+, P = 0.013; Fig. 4b ) and UT (0 vs 1+/2+/3+, P = 0.002; 0/1+ vs 2+/3+, P = 0.034; Fig. 4c ) were separately analyzed, UGT1A levels were still found to be a significant prognostic factor.
To determine whether UGT1A status was an independent prognosticator for UUTUC, we then carried out multivariate analysis using the Cox model (Table 2 ). In 90 patients with M0 disease, not only pT stage, but also UGT1A expression (hazard ratio 0.28, 95% CI 0.10-0.80, P = 0.018), was found to correlate with CSS.
UGT1A silencing and urothelial cancer cell growth
We previously showed that a bladder urothelial cancer cell line, UMUC3, expressed UGT1A. 8 We next assessed the effect of UGT1A silencing through its siRNA transfection on the proliferation and migration of UMUC3 cells to determine its functional role in urothelial cancer cell growth. We thus compared cell viability by MTT assay as well as cell migration by wound-healing assay between control UGT1A-positive line and its knockdown line. The expression of UGT1A-siRNA showed marked increases in cell viability ( Fig. 5a ) and cell migration (Fig. 5b) , compared with the control line.
Discussion
In the liver, UGTs are known to play a critical role in the elimination of numerous carcinogens by sequestration and excretion to the biliary or urinary tract. Although the liver is considered the most important organ in glucuronidation, UGTs are also expressed in some extrahepatic tissues, including the urinary bladder. 18 In the bladder, it is suggested that acidic urine promotes hydrolysis of glucronide-carcinogen to release ultimate carcinogens. 19 UGT1A, a major subtype for glucuronidation of bladder carcinogens, in bladder urothelium might thus serve as a critical protector for these carcinogens. 20 In the renal pelvis, the pH of the urine is lower than that in bladder, suggesting glucuronide-carcinogen can be hydrolyzed in the upper urinary tract as well. 21 However, UGT1A expression in the upper urinary tract has not yet been studied.
In the present study, we showed UGT1A expression in both tumors and adjacent normal tissues in the upper urinary tract for the first time. In accordance with our observations in bladder specimens, UGT1A expression was significantly downregulated in tumors, compared with normal urothelium. 8 These results suggest that reduced UGT1A expression correlates with the induction of urothelial tumorigenesis at both the upper and lower urinary tracts. In addition, in our previous study of UCB, UGT1A expression was downregulated in high-grade or stage tumors. 8 In UUTUC, however, UGT1A expression inversely correlated only with pT stage, but not tumor grade. A relatively small number of the patients with low-grade tumor (n = 15) in the current study might be a reason for this discrepancy. Loss or weak expression of UGT1A was also associated with the presence of other known prognostic factors, such as lymphovascular invasion and concomitant CIS, but not lymph node metastasis or hydronephrosis. Meanwhile, it was recently documented, in colon cancer lines, that knockdown of UGT1A resulted in an increase in cell proliferation through p53 inactivation, suggesting its function as a suppressor of tumor progression in addition to tumorigenesis. 22 Consistent with these in vitro data, we showed that silencing of UGT1A, compared with the control, strongly induced the viability as well as the migration of urothelial cancer cells. Furthermore, we previously found that UGT1A was lost in three metastatic urothelial tumors in the lymph node, and was weakly positive (1+) in the other three tumors (unpubl. data) while we stained our bladder TMAs for UGT1A, which might also support its suppressive role in urothelial cancer progression. 7, 8 The levels of UGT1A expression were found to precisely predict PFS and CSS in patients with M0 UUTUC. As expected, tumor stage was a very strong prognosticator, and most cancer-specific deaths were seen in patients with pT3-4 disease. We further found that UGT1A predicted CSS even in this high-risk group of patients. Multivariate analysis also showed UGT1A as an independent prognosticator for CSS. Thus, UGT1A could be a useful prognostic marker, especially for advanced UUTUCs. Interestingly, the levels of UGT1A expression were considerably higher in RPTs than in UTs. Using the same set of TMA, we recently showed marginal increases (P = 0.080) in the positivity of a transcription factor, NFATc1, which was shown to promote urothelial tumorigenesis and tumor progression, 23, 24 in RPTs (60.0%) compared with UTs (42.0%). 16 In contrast, in our recent studies, RPTs showed lower positive rates of other transcription factors, such as androgen receptor known to promote urothelial tumor outgrowth 7,25 (11.1% vs 28.0%, P = 0.070), 17 estrogen receptorb that could inhibit urothelial tumor outgrowth 8, 25 (51.1% vs 72.0%, P = 0.056), 17 GATA3 shown to function as a tumor suppressor 26, 27 (35.6% vs 66.0%, P = 0.004) ZKSCAN3 shown to function as an oncogene 29 (26.7% vs 54.0%, P = 0.012). 30 Thus, the expression patterns of these transcription factors are not well correlated with their functional roles (e.g. tumor suppressor vs oncogene). There were no significant differences in the positivity of other steroid hormone receptors, including estrogen receptor-a (22.2% vs 12.0%), glucocorticoid receptor (57.8% vs 68.0%) and progesterone receptor (8.9% vs 20.0%), in RPTs versus UTs. 17 The underlying reasons for these findings in the expression of UGT1A and these transcription factors remain undefined. However, as we previously suggested, differences in tissue preservation among RPTs, UTs and UCBs as a result of their anatomical locations and/or thickness of the specimens around the tumors (e.g. time to complete tissue fixation) might have affected the immunoreactivity. 16, 17, 23 Another possibility includes a higher proportion of superficial disease (pTa or pT1), where UGT1A expression is more likely strong, in RPTs (44.4%) compared with UTs (34.0%). Nevertheless, even when we analyzed RPT and UT separately, UGT1A expression was a strong prognosticator for both RPT and UT. Of note, there was no significant difference in the levels of UGT1A expression between benign portions of renal pelvic versus ureteral urothelium, as well as those of upper urinary tract vs bladder urothelium.
In conclusion, we showed reduced UGT1A expression in UUTUC compared with normal-appearing urothelium from each case. In addition, the levels of UGT1A expression correlated with tumor progression and UGT1A positivity was an independent prognosticator for better outcomes. Furthermore, UGT1A knockdown in a urothelial cancer line resulted in considerable induction in cell viability and migration. These results suggest that UGT1A contributes to the prevention of UUTUC outgrowth. Further functional analyses of UGT1A in urothelial cells are necessary to determine their biological significance.
